期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

胰高血糖素样肽-1受体激动剂在神经系统疾病治疗中的研究进展 被引量：8

Advances of glucagon-like peptide-1 receptor agonists in the treatment of nervous system diseases
下载PDF
导出
摘要 肠促胰素型糖尿病治疗药物胰高血糖素样肽-1(GLP-1)在人体作用广泛,GLP-1受体在人体分布广泛且疗效多样。研究表明,除治疗糖尿病外,GLP-1受体激动剂在中枢和外周神经系统均能发挥良好的神经保护和抗感染作用,显示了良好的应用前景。本文综述了近年来GLP-1受体激动剂在阿尔茨海默病、帕金森病、脑卒中等神经系统疾病中的临床前和临床治疗中的研究进展。 The novel incretin-based diabetic drug, glucagon like peptide-1 （GLP-1）, has a range of physiological effects. The widespread distribution of GLP-1 receptors also determines the pleiotropy of GLP-1 receptor agonists. Recent studies suggest that, in addition to anti-diabetic use, GLP-1 receptor agonists exert neuroprotective and anti-inflammatory effects in both central and peripheral nervous systems. Therefore, GLP-1 receptor agonists show great potential as novel preventive or therapeutic agents for neurodegenerative conditions. This article mainly reviews the recent pre-clinical and clinical studies about GLP-1 receptor agonists applied in Alzheimer＇s disease, Parkinson＇s disease, stroke and other neurological diseases.
作者 印蕾 王影 陈松 高向东
机构地区 中国药科大学生命科学与技术学院
出处 《中国药科大学学报》 CAS CSCD 北大核心 2014年第4期383-391,共9页 Journal of China Pharmaceutical University
基金 国家自然科学基金资助项目(No.81273496 No.81302780) 国家高技术研究发展计划(863计划)资助项目(No.2013AA092901)~~
关键词 胰高血糖素样肽-1 胰高血糖素样肽-1受体激动剂 神经系统疾病 研究进展 glucagon-like peptide-1 glucagon-like peptide-1 receptor agonist neurological diseases advances
分类号 R741 [医药卫生—神经病学与精神病学]
  • 相关文献

参考文献39

  • 1Lund A, Knop FK, Vilsb:ll T. Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes : differences and simi- larities [ J ]. Eur J Intern Med,2014,25 (5) :407 - 414.
  • 2Lauritsen K, Christensen K, Stokholm K. Gastric inhibitory poly- peptide (GIP) release and incretin effect after oral glucose in obesity and after jejunoileal bypass[J]. Scand J Gastroenterol, 1980,15(4) :489 -495.
  • 3Bell GI, Sanchez PR, Laybourn PJ, et al. Exon duplication and divergence in the human preproglucagon gene [ J ]. Nature, 1983, 304:368 -371.
  • 4Drueker D J, Philippe J, Mojsov S, et al. Glucagon-like peptide 1 stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line[ J]. Proc Natl Acad Sci U S A, 1987, 84(10) :3 434 -3 438.
  • 5Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1 [ J ]. Proc Natl Acad Sci U S A, 1992,89 ( 18 ) : 8 641 - 8 645.
  • 6Pyke C, Heller RS, Kirk RK, et al. GLP-1 receptor localization in monkey and human tissue:novel distribution revealed with exten- sively validated monoclonal antibody [ J ]. Endocrinology, 2014, 155 (4) : 1 280 - 1 290.
  • 7周映红,黄文龙,张惠斌,迟玉石.GLP-1受体激动剂及DPP-Ⅳ抑制剂的研究进展[J].中国药科大学学报,2008,39(5):385-391. 被引量：28
  • 8Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sus- tained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide [ J ]. Int J Obesity,2012,36 (6) : 843 - 854.
  • 9Eng J, Kleinman WA, Singh L, et al. Isolation and characteriza- tion of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas[ J]. J Biol Chem, 1992, 267 ( 11 ) :7 402 - 7 405.
  • 10Werner U, Haschke G, Herling AW,et al. Pharmacological profile of lixisenatide : a new GLP-1 receptor agonist for the treatment of type 2 diabetes[ J]. Regul Peptides,2010,164(2) :58 -64.

二级参考文献28

  • 1马义,周天鸿.胰高血糖素样肽1的研究及应用进展[J].中国组织工程研究与临床康复,2007,11(29):5806-5809. 被引量：10
  • 2Nakagawa A, Satake H, Nakabayashi H, et al. Receptor gene expression of glucagons like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglin cells[ J ]. Auton Neurosci,2004,110( 1 ) :36 -43.
  • 3Bulotta A, Hui H, Anastasi e, et al. Cultured pancreatic ductal cells undergo cell cycle re-distribution and beta-cell like differentiation in response to glucogan-like peptide-1 [ J]. J Mol Endocrion1,2002,29 ( 3 ) :347 - 360.
  • 4Wang YP, Liu LB. Protection of glucagon-like peptide-1 on pancreatic fl-cell [ J ] . Int J Endocrinol Metab, 2007,27 ( 2 ) : 98 - 100.
  • 5Chee WC, Josephine ME. Biology and therapeutic potential of GLP-1 in the treatment of diabetes [ J ]. Drug Discov Today Dis Mech ,2005,2 ( 3 ) :295 - 301.
  • 6Ahren B, Olsson ML, Jansson PA, et al. Inhibition of dipeptidyl peptidase-r reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes [ J ]. J Clin Endocrinol Metab , 2004,89(5) :2 078 -2 084.
  • 7Little TJ, Pilichiewicz AN, Russo A, et al. Effects of Intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects:relationships with postprandial glycemic and insulinemic responses [ J ]. J Clln Endocrinol Metab ,2006,91(5) :1 916-1 923.
  • 8Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes[ J]. Lancet,2006,368 ( 1 ! ) : 1 696 - 1 705.
  • 9Gotthardt M, Lalyko G, van Eerd-Vismale J, et al. A new technique for in vivo imaging of specific GLP-1 binding sites : First results in small rodents [ J ]. Regul Pept,2006,137 ( 3 ) : 162 - 167.
  • 10Hagemann D, Holst JJ,Gethmann A,et al. Glucagon-like peptide 1 (GLP-1)suppresses ghrelin levels in humans via increased insulin secretion [ J ]. Regul Pept ,2007 ,143 ( 1-3 ) : 64 - 68.

共引文献27

同被引文献65

  • 1肖元元, 徐淼, 刘若冰,等. 肝细胞脂肪性病变对胰高血糖素样肽1受体表达的影响[J]. 中华临床医师杂志(电子版), 2013,7(22):10118-10123.
  • 2Salehi M, Aulinger BA, D'Alessio DA. Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins [J]. Endocr Rev, 2008,29(3 ) :367-379. DOI: 10. 1210/er. 2007- 0031.
  • 3Noyan-Ashraf MH, Momen MA, Ban K, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice [ J ]. Diabetes, 2009,58 (4) :975-983. DOI: 10. 2337/db08-1193.
  • 4Okerson T, Yan P, Stonehouse A, et al. Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes [ J ]. Am J Hypertens, 2010,23 ( 3 ) :334-339. DOI : 10. 1038/ajh. 2009. 245.
  • 5Ishibashi Y, Nishino Y, Matsui T, et al. Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level [ J ]. Metabolism, 2011, 60(9 ) : 1271-1277. DOI: 10. 1016/j. lnetabol. 2011.01. 010.
  • 6Mieczkowska A, Mansur S, Bouvard B, et al. Double incretin receptor knock-out ( DIRKO ) mice present with alterations of trabecular and cortical micromorphology and bone strength [J]. Osteoporos Int, 2015, 26( I ) :209-218. DOI: 10. 1007/s00198)14-2845-8.
  • 7Yamada C, Yamada Y, Tsukiyama K, et al. The murine glucagon-like peptide-I receptor is essential for control of bone resorption [ J ]Endocrinology, 2008,149 (2) : 574-579. DOI: 10. 1210/en. 2007- 1292.
  • 8Sanz C, V6zquez P, Bl6zquez C, et al. Signaling and biological effects of glucagon-like peptide 1 on the differentiation of mesenchymal stem cells from human bone marrow [ J ]. Am J Physiol Endocrinol Metab, 2010,298 ( 3 ) : E634-E643. DOI : 10.1152/ajpendo. 00460. 2009.
  • 9Nuche-Berenguer B, Moreno P, Esbrit P, et al. Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin- resistant states[ J ]. Calcif Tissue Int, 2009,84 ( 6 ) : 453461. DOI : 10.1007/s00223-009 -9220 -3.
  • 10Jiang Z, Von den Hoff JW, Torensma R, et al. Wntl6 is involved in intramembranous ossification and suppresses osteoblast differentiation through the Wnt/13-catenin pathway [ J ]. J Cell Physio1,2014 ,229 ( 3 ) : 384-392. DOI : 10. 1002/jcp. 24460.

引证文献8

二级引证文献31

中国药科大学学报
2014年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部